Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Nanjing Jingjie Biotechnology

Explore full profile

Precision point-of-care in-vitro diagnostic and monitoring devices

Nanjing City, ChinaFounded 2017Health Tech & Medtech
Valuation $100–250M Last recorded · 2023
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Nanjing Jingjie Biotechnology and the history behind them.

About Nanjing Jingjie Biotechnology

Nanjing Jingjie Biotechnology Co., Ltd., operating as Eaglenos Sciences, is a biotechnology company founded in 2018 that develops, manufactures, and markets diagnostic devices. The company is headquartered in Nanjing, China, and has expanded to establish a research and development base of over 7,500 square meters.

Eaglenos specializes in precise point-of-care testing (POCT) products for home and clinical settings, focusing on chronic diseases like diabetes and cardiovascular conditions. Its product lineup features three main platforms: cartridge testing, paper-strip testing, and dynamic monitoring. Key products include multi-functional monitoring meters for blood glucose, uric acid, lactate, and ketones, as well as blood gas and electrolyte analyzers for acute care settings like ICUs and emergency rooms. These devices are engineered using the company's core technologies in electrochemistry, microfluidics, and signal acquisition.

The company serves both individual users and medical institutions, offering digital data management platforms and integrated health solutions to complement its hardware. Eaglenos generates revenue through the production and sale of its diagnostic devices, wearable monitoring systems, and health management products. The company is privately held and venture capital-backed, having secured a Series A funding round of $22 million in February 2023.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2017
Headquarters
Nanjing City, China
Employees
48
Open positions
1
Dealroom signal
55.8/100
Industry
Health
Sub-industry
Medical Devices
Sector
Health Tech & Medtech, Hard Tech
Client focus
b2b

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC May 2023 $21M $83M Huatai Zijin Investment · Innomed Capital · Shanghai Changjiang Guohong Investment Management · 3E Bioventures ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Nanjing Jingjie Biotechnology website traffic

Latest recorded traffic for Nanjing Jingjie Biotechnology is 13K monthly website visits, up 622.2% over the last three months. Nanjing Jingjie Biotechnology's team grew 2300% over the past year.

Latest monthly visits13K 3-month web change+622.2% 1-year team growth+2300%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom
1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Huatai Zijin Investment
  • Innomed Capital
  • Shanghai Changjiang Guohong Investment Management
  • 3E Bioventures
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
9 countries with
team presence
🇨🇳 China65.5%
🇺🇸 United States10.3%
🇨🇦 Canada3.5%
🇳🇬 Nigeria3.5%
🇪🇸 Spain3.5%
Top 5 of 9 shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Nanjing Jingjie Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Nanjing Jingjie Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.